Herba siegesbeckiae composition and application of herba siegesbeckiae composition in preparing medicine for preventing and treating tumor heart disease
Through the singling composition composed of singling singling, singling pilosula and Polygonatum extract, the cardiotoxicity caused by doxorubicin in anti-tumor treatment was solved, significantly improved cardiomyocyte viability and restored myocardial tissue, and provided effective Methods for preventing and treating tumor heart disease.
Patent Information
- Application Number
- CN202310595841.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-25
- Publication Date
- 2024-11-26
AI Technical Summary
The existing technology cannot effectively prevent and treat cardiotoxicity caused by anti-tumor treatment, especially cardiotoxicity caused by the anthracycline drug doxorubicin. The existing prevention and treatment strategies are expensive and have obvious adverse reactions, and lack effective prevention and treatment methods.
The squid composition composed of squid, squid and polysin extract is used to prepare drugs for preventing and treating tumor heart disease through the mixing of different mass ratios, which significantly reduces myocardial damage and restores myocardial tissue structure.
The squid composition significantly improves the viability of cardiomyocytes in rats induced by doxorubicin, inhibits the release of myocardial damage enzymes, reduces myocardial damage, restores myocardial tissue morphological structure, and reduces myocardial fibrosis, providing an effective prevention and treatment strategy for tumor heart disease. .
Smart Images

Figure CN119015369A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a Chinese medicine composition and application, in particular to a Siegesbeckia scoparia composition and application in preparing medicines for preventing and treating tumor heart disease. Background Art
[0002] With the extension of the treatment time and survival period of cancer patients, the cardiotoxicity caused by anti-tumor therapy has been increasingly recognized and concerned, and has become the second leading cause of death in cancer patients after recurrence and metastasis. Long-term cardiovascular complications caused by anti-tumor therapy are a major problem. Based on this, an emerging interdisciplinary discipline, oncology cardiology, has emerged. Its broad concept includes cardiovascular toxicity caused by anti-tumor therapy, tumors with cardiovascular diseases, common risk factors of tumors and cardiovascular diseases, and cardiac space-occupying lesions. Its narrow concept refers to cardiovascular toxicity caused by anti-tumor therapy. At present, research in the field of oncology cardiology is mainly focused on its narrow concept. The primary goal of this discipline is to make cancer treatment safer from a cardiovascular perspective and improve the quality of life and survival of patients. The anthracycline drug doxorubicin (DOX) is a commonly used broad-spectrum anti-tumor drug in clinical practice. Long-term use can cause severe cardiotoxicity. Dexrazoxane is the only drug approved by the US Food and Drug Administration (FDA) for the treatment of doxorubicin-induced cardiotoxicity, but it has not been widely used in clinical practice due to its high price and obvious adverse reactions. Angiotensin-converting enzyme inhibitors (ACEIs) / angiotensin receptor blockers (ARBs) can be used to prevent cancer treatment-related cardiovascular toxicity, but clinical evidence is insufficient and whether they are beneficial remains controversial. Therefore, effective prevention and treatment strategies are still needed to meet this challenge.
[0003] Traditional Chinese medicine has the advantages of overall regulation, diverse methods, and prevention before illness occurs, and may fill the existing gaps in this field. Studies have shown that traditional Chinese medicine can reduce the cardiotoxicity caused by anthracyclines, better maintain left ventricular ejection fraction and ventricular internal diameter, reduce myocardial injury markers, and reduce myocardial injury. It has potential preventive and therapeutic value in the field of tumor heart disease. According to traditional Chinese medicine, tumor heart disease belongs to the categories of "palpitations", "chest pain", "phlegm and fluid", etc., and is a syndrome of deficiency in the root and excess in the superficial. The disease is located in the heart meridian, and the pathogenesis can be summarized as "toxic damage to the heart meridian". "Toxic damage" is the key to the pathogenesis, and "collateral deficiency" is the basis for the onset of the disease. Detoxification, unblocking the meridians, and replenishing qi and nourishing yin are its treatment methods.
[0004] At present, there is no report on the use of a composition composed of Siegesbeckia sibiricum, Periploca odorata and Polygonatum sibiricum in preparing a drug for preventing and treating tumor heart disease. Summary of the invention
[0005] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a Xijiajing composition capable of preventing and treating tumor heart disease.
[0006] The second object of the present invention is to provide an application of a Xijiajing composition in the preparation of drugs for preventing and treating tumor heart disease.
[0007] The technical solution of the present invention is summarized as follows:
[0008] The Siegesbeckia sibiricum composite consists of Siegesbeckia sibiricum extract, Periploca odorata cortex extract and Polygonatum sibiricum extract.
[0009] Preferably, the mass ratio of the Siegesbeckia scoparia extract, the Periploca odorata extract and the Polygonatum sibiricum extract is 4:1:(8-16).
[0010] The application of the above-mentioned Xijiajing composition in the preparation of drugs for preventing and treating tumor heart disease.
[0011] Advantages of the present invention:
[0012] (1) Cell experiments have shown that the Xijiajing composition of the present invention can improve the viability of rat H9c2 cardiomyocytes induced by adriamycin.
[0013] (2) Animal experiments have shown that the Xijiajing composition can significantly inhibit the release of high sensitivity cardiac troponin I (hs-cTnI), an enzyme that damages the myocardium of mice induced by adriamycin, and reduce myocardial damage.
[0014] (3) Animal experiments have shown that the Xijiajing composition can significantly restore the myocardial tissue morphology and structure of mice induced by adriamycin, and can significantly reduce myocardial fibrosis in mice induced by adriamycin. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 The effect of different ratios of Xijiajing composition on the viability of rat H9c2 cardiomyocytes induced by doxorubicin.
[0016] Figure 2 The effect of Xijiajing composition on hs-cTnI, an enzyme that causes myocardial injury in mice induced by adriamycin.
[0017] Figure 3 To study the effect of Xijiajing composition on the morphological structure of myocardial tissue in doxorubicin-treated mice.
[0018] Figure 4 Effects of Xijiajing composition on myocardial fibrosis in doxorubicin-treated mice. DETAILED DESCRIPTION
[0019] The Siegesbeckia herba slices of each embodiment of the present invention were purchased from Beijing Jinchongguang Pharmaceutical Co., Ltd. (batch number: C5171131), the Periploca odorata slices were purchased from Beijing Shengshilong Pharmaceutical Co., Ltd. (batch number: 1812028), and the Polygonatum sibiricum slices were purchased from Beijing Shengshilong Pharmaceutical Co., Ltd. (batch number: 2111053). The disclosure of the sources of the various slices of the present invention is to better illustrate the present invention, and does not limit the sources of the slices of the present invention.
[0020] Xijiajing combination, referred to as XJJ; it can also be called Xijiajing prescription.
[0021] Example 1
[0022] Preparation of Siegesbeckia sibiricum extract, Periploca odorata extract and Polygonatum sibiricum extract:
[0023] Add 4L (or 5L) of water to 500g of Siegesbeckia sibiricum, soak for 30min, boil at 100℃ for 30min, filter to obtain residue and filtrate, add 3L (or 4L) of water to the residue, boil at 100℃ for 30min; filter, combine the two filtrates, concentrate, and freeze-dry to obtain Siegesbeckia sibiricum extract.
[0024] 500 g of each of Periploca odoratum and Polygonatum sibiricum were taken and prepared according to the above-mentioned preparation method of Siegesbeckia sibiricum extract to obtain Periploca odoratum extract and Polygonatum sibiricum extract, respectively.
[0025] The extract of Siegesbeckia sibiricum, the extract of Periploca odorata and the extract of Polygonatum sibiricum are mixed in a mass ratio of 4:1:8 to form a Siegesbeckia sibiricum composition, referred to as XJJ (4:1:8);
[0026] The Siegesbeckia sibiricum extract, the Periploca odorata extract and the Polygonatum sibiricum extract are mixed in a mass ratio of 4:1:12 to form a Siegesbeckia sibiricum extract composition, referred to as XJJ (4:1:12);
[0027] The Siegesbeckia sibiricum composite is prepared by mixing Siegesbeckia sibiricum extract, Periploca odorata cortex extract and Polygonatum sibiricum extract in a mass ratio of 4:1:16, referred to as XJJ (4:1:16).
[0028] Example 2
[0029] Effects of different ratios of Xijiajing compositions on the viability of rat H9c2 cardiomyocytes induced by doxorubicin.
[0030] Experimental Materials
[0031] (1) Reagents: DMEM medium (glucose concentration 4.5 g / L), pH = 7.4 PBS buffer (hereinafter referred to as PBS), fetal bovine serum, 0.25% EDTA trypsin, Cell Counting Kit-8 (NCM Biotech, 20230208).
[0032] (2) Instruments: CO2 incubator, electric constant temperature water bath, normal temperature high-speed desktop centrifuge, vertical laminar flow clean bench, fully automatic microplate reader (MULTISKAN MK3, Thermo, USA).
[0033] Experimental methods
[0034] (1) The H9c2 cardiomyocyte cell line was purchased from the National Laboratory Cell Resource Sharing Platform: http: / / www.cellresource.cn on April 19, 2023 and frozen in liquid nitrogen.
[0035] Cell recovery: Prepare a cell culture bottle in the clean bench in advance and add 5 ml of DMEM complete medium (DMEM medium containing 10% fetal bovine serum). Quickly transfer the frozen H9c2 cardiomyocytes from the liquid nitrogen tank to a 37°C water bath, shake until dissolved, disinfect with 75% alcohol and place in the clean bench, aspirate with a pipette, add to the culture bottle containing DMEM complete medium, shake evenly and place in a 37°C CO2 incubator. After 24 hours, replace DMEM complete medium and observe the cell density. When it reaches more than 70%, replace DMEM complete medium until the cell density reaches 80%-90%.
[0036] Cell passaging: Place DMEM complete medium, PBS, and 0.25% EDTA trypsin in a 37°C water bath in advance, disinfect with 75% alcohol after reaching room temperature, and place in a clean bench. Discard the medium, wash with PBS three times, add 1 ml of 0.25% EDTA trypsin to the cell culture bottle, incubate in a 37°C CO2 incubator for 1 min, and observe under a microscope. When the cells shrink and become round and tend to fall off, add 2 ml of DMEM complete medium to the culture bottle to stop digestion. After the cells are fully blown by the pipette, transfer them to a centrifuge tube, centrifuge at 1000 rpm / , 5 min, discard the supernatant, add DMEM complete medium, and prepare H9c2 cell suspension.
[0037] (2) H9c2 cell suspension was cultured in DMEM complete medium at a rate of 1×10 5 / ml were inoculated in a 96-well culture plate (100 μL / well), and blank wells were reserved for adding only DMEM complete medium. The culture plate was placed in a 37°C CO2 incubator for 24 hours, and then the original medium was discarded. PBS was added for washing, and then DMEM complete medium containing different drugs was added to each well to divide the groups:
[0038] ① Control group: H9c2 cardiomyocytes were incubated with DMEM complete medium for 24 h;
[0039] ② Doxorubicin group (DOX): H9c2 cardiomyocytes were incubated with DMEM complete medium containing 6.25 μM DOX for 24 h;
[0040] ③XJJ (4:1:8) + DOX group: first incubated with DMEM complete medium containing 50 μg / ml XJJ (4:1:8) for 3 h, then added with 6.25 μΜ DOX and incubated for 24 h;
[0041] ④XJJ (4:1:12) + DOX group: first incubated with DMEM complete medium containing 50 μg / ml XJJ (4:1:12) for 3 h, then added with 6.25 μΜ DOX and incubated for 24 h;
[0042] ⑤XJJ (4:1:16) + DOX group: first incubate with DMEM complete medium containing 50 μg / ml XJJ (4:1:16) for 3 h, then add 6.25 μΜ DOX and incubate for 24 h.
[0043] (3) The original culture medium was discarded, and a 10% CCK-8 solution (100 μl / well) was added to each well, and the cells were incubated in a CO2 incubator for 2 h away from light.
[0044] (4) The absorbance at 450 nm was measured using an enzyme-labeled instrument, and the cell viability of each group was calculated according to the following formula.
[0045] As: absorbance of experimental wells (containing cells, culture medium, CCK-8 solution, and drug solution);
[0046] Ac: absorbance of control well (containing cells, culture medium, CCK-8 solution, but no drug);
[0047] Ab: absorbance of blank wells (containing culture medium, CCK-8 solution, no cells, no drugs);
[0048] Cell viability (%) = [(As-Ab) / (Ac-Ab)] × 100%.
[0049] (5) GraphPad Prism 8 software was used to perform statistical analysis on the cell viability of each group and to plot the graphs. Figure 1 .
[0050] Experimental Results
[0051] The cell viability of H9c2 cardiomyocytes in each experimental group is shown in Table 1.
[0052] Table 1 Cell viability of H9c2 cardiomyocytes in each experimental group
[0053]
[0054] Note:* P<0.05vs Control group, ## P<0.01 vs DOX group, n=3.
[0055] The results in Table 1 show that compared with the Control group, the viability of H9c2 cardiomyocytes in the DOX group ( Figure 1 ) decreased significantly (P<0.05); compared with the DOX group, different proportions of the Xi Jia Jing compositions of the present invention can restore cell viability to varying degrees (P<0.01); the results show that the Xi Jia Jing compositions can significantly restore the decreased viability of H9c2 cells caused by anti-tumor drugs and reduce cell damage.
[0056] Example 3
[0057] The method for establishing the mouse adriamycin myocardial injury model, grouping and drug administration includes the following steps:
[0058] Male C57BL / 6J mice, 7-8 weeks old, 23-25 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.; the drugs were all XJJ (4:1:8) compositions prepared in Example 1.
[0059] (1) Sixty male C57BL / 6J mice were randomly divided into six groups, with 10 mice in each group.
[0060] ① Blank control group (Control): The mice were given normal saline with the same volume as the drug by gavage for 4 weeks;
[0061] ② Doxorubicin group (DOX): C57BL / 6J mice were intraperitoneally injected with doxorubicin 5 mg / kg once a week for 4 weeks;
[0062] ③ Low-dose Xijiajing composition (4.929 g / kg) + doxorubicin group (XJJL+DOX): C57BL / 6J mice were given 4.929 g / kg of Xijiajing composition by gavage once a day for 4 weeks, and 5 mg / kg of doxorubicin was injected intraperitoneally 30 minutes after the first gavage, and then once a week for 4 weeks;
[0063] ④ The medium dose of Xijiajing composition (9.858 g / kg) + doxorubicin group (XJJM+DOX): C57BL / 6J mice were given 9.858 g / kg of Xijiajing composition by gavage once a day for 4 weeks, and 5 mg / kg of doxorubicin was injected intraperitoneally 30 minutes after the first gavage, and then once a week for 4 weeks;
[0064] ⑤ High-dose Xijiajing composition (19.716 g / kg) + doxorubicin group (XJJH+DOX): C57BL / 6J mice were given 19.716 g / kg of Xijiajing composition by gavage once a day for 4 weeks, and 5 mg / kg of doxorubicin was injected intraperitoneally 30 minutes after the first gavage, and then once a week for 4 weeks;
[0065] ⑥ Dexrazoxane (50 mg / kg) + doxorubicin group (DEX+DOX): C57BL / 6J mice were intraperitoneally injected with 50 mg / kg dexrazoxane, and 30 minutes later, intraperitoneally injected with doxorubicin 5 mg / kg, once a week for 4 consecutive weeks.
[0066] (2) After 4 weeks, serum myocardial injury enzymes, myocardial tissue morphology and structure, and myocardial fibrosis were detected in each group of mice.
[0067] Example 4
[0068] Effect of Xijiajing composition (XJJ 4:1:8) on myocardial injury enzyme hs-cTnI in adriamycin-induced mice.
[0069] Experimental Materials
[0070] (1) Reagents: Mouse high-sensitive cardiac-specific troponin I (hs-cTnI) ELISA kit (E20230330-22975B).
[0071] (2) Instruments: 37°C constant temperature and humidity chamber, microplate reader (MULTISKAN MK3, Thermo, USA).
[0072] Experimental methods
[0073] (1) Serum sample collection and processing
[0074] After 4 weeks of intervention, whole blood was collected from mice in each group by removing the eyeball, and the specimens were centrifuged at 3000 rpm for 15 minutes at 4°C within 30 minutes after collection, and the supernatant was taken for detection.
[0075] (2) ELISA operation steps
[0076] ①Take the test kit out of the refrigerated environment and equilibrate it at room temperature;
[0077] ② Take out the required microporous enzyme strips from the aluminum foil bag after equilibration at room temperature for 20 minutes;
[0078] ③ Set up standard wells and sample wells, and add 50 μL of standard of different concentrations to each standard well;
[0079] ④ Add 50 μL of the sample to be tested to the sample well, and nothing to the blank well;
[0080] ⑤Except for the blank wells, add 100 μL of detection antibody labeled with horseradish peroxidase (HRP) to each of the standard wells and sample wells, seal the reaction wells with a sealing film, and incubate in a constant temperature and humidity chamber at 37°C for 60 min.
[0081] ⑥Discard the liquid, pat dry on absorbent paper, fill each well with washing solution (350 μL), let stand for 1 min, shake off the washing solution, absorb
[0082] Pat dry on water paper, repeat this process 5 times;
[0083] ⑦ Add 50 μL of substrate colorimetric reagent A and B to each well and incubate at 37°C in the dark for 15 min;
[0084] ⑧ Add 50 μL of stop solution to each well and measure the OD value of each well at a wavelength of 450 nm within 15 minutes.
[0085] (3) Calculation of experimental results
[0086] Use Excel to draw a standard curve on the coordinate paper with the OD value of the measured standard as the horizontal axis and the concentration value of the standard as the vertical axis, and obtain a linear regression equation. Substitute the OD value of the sample into the equation to calculate the concentration of the sample.
[0087] Experimental Results
[0088] The levels of hs-cTnI in the serum of mice in each group are shown in Table 2.
[0089] Table 2 hs-cTnI levels in serum of mice in each experimental group
[0090]
[0091] Note: ** P<0.01vs Control group, ## P<0.01vs DOX group.
[0092] The results in Table 2 show that compared with the Control group, the hs-cTnI ( Figure 2 ) was significantly increased (P<0.01); compared with the DOX group, different doses of the Xi Jia Jing composition of the present invention can reduce the content of hs-cTnI in the serum of DOX mice to varying degrees (P<0.01); the results show that the Xi Jia Jing composition can significantly reduce the myocardial damage of mice caused by anti-tumor drugs.
[0093] Example 5
[0094] Effects of Xijiajing combination (XJJ 4:1:8) on the morphological structure of myocardial tissue in doxorubicin-treated mice.
[0095] Experimental Materials
[0096] (1) Reagents: 4% paraformaldehyde, ethanol, xylene, Harris hematoxylin stain, and eosin stain.
[0097] (2) Instruments: Leica ASP300S fully automatic dehydrator, paraffin embedding machine, rotary paraffin sectioner, optical microscope.
[0098] Experimental methods
[0099] After 4 weeks of intervention, the mice in each group were opened to remove the mouse hearts, fixed with 4% paraformaldehyde for 48 hours, dehydrated in a fully automatic dehydrator with 50%-70%-80%-95%-100% ethanol, transparentized with xylene, and immersed in wax. The tissue wax blocks were embedded in a paraffin embedding machine, and finally 5μm thick continuous paraffin sections were made using a rotary paraffin sectioning machine. The HE staining steps are as follows:
[0100] ① Preparation: Place the slices to be stained with HE in a 60° oven for 60 minutes.
[0101] ② Dewaxing to water: Dewaxing the prepared paraffin sections in xylene for 15 minutes; then start hydrating from high concentration to low concentration gradient: soak in each solution tank for 2-5 minutes in the order of anhydrous ethanol, 95% ethanol, 90% ethanol, 70% ethanol, 60% ethanol, and 50% ethanol. After the above steps, rinse with running water for 5 minutes.
[0102] ③ Staining: Place the dewaxed sections in a Harris hematoxylin staining solution for 10 minutes, rinse with running water for 1 minute, differentiate with 1% hydrochloric acid ethanol for 30 seconds, wash thoroughly with tap water, blue for 10 minutes, stain with 1% eosin solution for 3 minutes, and rinse with running water for 1 minute.
[0103] ④ Dehydration: Dehydrate step by step from low concentration to high concentration, soak in 50% ethanol, 60% ethanol, 70% ethanol, 80% ethanol, 90% ethanol, 95% ethanol, and anhydrous ethanol for 2 minutes respectively;
[0104] ⑤ Transparency: The dehydrated slices were soaked in xylene twice for 10 minutes each time, and finally sealed with neutral gum.
[0105] ⑥ Take photos: Observe the damage of myocardial cells under a microscope and select the appropriate magnification to take photos and record them.
[0106] Experimental Results
[0107] like Figure 3As shown, it is an image taken under ×40 objective lens. It can be seen that the myocardial tissue morphology and structure of the mice in the Control group are normal: the myocardial fibers are arranged neatly; the cell nuclei are clear, evenly colored and of uniform size, there is no inflammatory cell infiltration, and there is little fibrous tissue between cells. Compared with the Control group, the myocardial tissue damage of the mice in the DOX group was obvious: the myocardial fibers were irregularly arranged, the gaps were enlarged, the coloring was uneven, the myocardial cell cytoplasm was loose and swollen, and severe watery degeneration occurred (as shown by the arrows). Different concentrations of the Xijiajing composition of the present invention can alleviate the myocardial tissue degeneration caused by DOX to varying degrees and restore the myocardial tissue structure.
[0108] Example 6
[0109] Effect of Xijiajing combination (XJJ 4:1:8) on myocardial fibrosis in mice with adriamycin-induced myocardial injury.
[0110] Experimental Materials
[0111] Reagents: Masson's trichrome staining kit.
[0112] Experimental method: Masson staining
[0113] ① Preparation: Place the Masson-stained sections in a 60° slide oven for 60 minutes.
[0114] ② Dewaxing to water: Dewaxing the prepared paraffin sections in xylene for 15 minutes; then start hydrating from high concentration to low concentration gradient: soak in each solution tank for 2-5 minutes in the order of anhydrous ethanol, 95% ethanol, 90% ethanol, 70% ethanol, 60% ethanol, and 50% ethanol. After the above steps, rinse with running water for 5 minutes.
[0115] ③ Staining: Soak the sections in the pre-prepared Weigert iron hematoxylin staining solution for 10 minutes, differentiate with acidic ethanol differentiation solution for 10 seconds, rinse with pure water for 10 seconds, return to blue with Masson blueing solution for 5 minutes, rinse with pure water for 1 minute, stain with Ponceau fuchsin for 8 minutes, rinse with weak acid solution (distilled water: weak acid solution = 2:1) for 1 minute, wash with phosphomolybdic acid solution for 2 minutes, rinse with weak acid solution for 1 minute, stain with aniline blue dye for 90 seconds, and wash with weak acid solution for 1 minute.
[0116] ④ Dehydration: Rapid dehydration in 95% ethanol solution once, and dehydration in anhydrous ethanol three times, each time for 5 seconds.
[0117] ⑤ Transparency: The dehydrated slices were soaked in xylene twice for 2 minutes each time, and finally sealed with neutral gum.
[0118] ⑥ Take photos: Observe myocardial fibrosis under a microscope and select an appropriate magnification to take photos and record them.
[0119] Experimental Results
[0120] like Figure 4 The images shown are taken under a ×20 objective lens, in which the blue-dyed ones represent collagen fibers. It can be seen that very small amounts of collagen fibers were visible in the intercellular spaces between the myocardial cells of the mice in the Control group; the myocardial cells had normal morphological structures, and were densely and neatly arranged. Large areas of blue-dyed collagen fibers (as shown by the arrows) were visible in the myocardial tissue of the mice in the DOX group, and the myocardial fibers were disorderly arranged. Different concentrations of the Xijiajing composition of the present invention can alleviate myocardial fibrosis to varying degrees: with the increase in the drug concentration, the arrangement of myocardial cells gradually became neater and denser, the intercellular spaces narrowed, and the collagen fiber content decreased.
[0121] Experiments have shown that the Xijiajing combination (XJJ 4:1:12) and the Xijiajing combination (XJJ 4:1:16) can also significantly reduce myocardial damage induced by doxorubicin in mice, restore the morphological structure of myocardial tissue, and reduce myocardial fibrosis.
Claims
1. A composition of Xiji plus essence, characterized in that It is composed of Siegesbeckia sibiricum extract, Periploca odorata extract and Polygonatum sibiricum extract.
2. The composition according to claim 1, characterized in that The mass ratio of the Siegesbeckia sibiricum extract, the Periploca odorata extract and the Polygonatum sibiricum extract is 4:1:(8-16).
3. Use of the Xijiajing composition according to claim 1 or 2 in the preparation of drugs for preventing and treating tumor heart disease.
Citation Information
Patent Citations
Glycyrrhiza extract for alleviating cardiotoxicity of medicine and application
CN101284042A
Application of songorine in medicine for resisting doxorubicin cardiotoxicity
CN114306334A
Application of herba siegesbeckiae aqueous extract in preparation of medicine for improving myocardial reperfusion injury
CN115969892A
Herba siegesbeckiae composition and application of herba siegesbeckiae composition in preparation of medicine for preventing and treating arrhythmia caused by antitumor medicine
CN119015354A
Effective extract of Chinese silkuine bark with cardotonic function and its preparing process and uasge
CN1593503A
